UNSPSC 51162731: Oxedrine

This classification denotes an adrenergic alpha-agonist, nasal decongestant, sympathomimetic, and vasoconstrictor agent with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PEG5DP7434, chemically known as benzyl alcohol, p-hydroxy-alpha-((methylamino)methyl)- but more generally known as oxedrine, which bears US NIH Compound Identifier 7172. European Medicines Agency schedules Oxedrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14726MIG.

World Health Organization schedules oxedrine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, OXEDRINE remains US FDA's Preferred Term for this commodity. SMILES: OC(CNC)C1CCC(O)CC1.

UNSPSC 51162731 Oxedrine is a Commodity code that encompasses pharmaceutical products and related services for state and local healthcare delivery, particularly correctional and community health settings. State and local governments procure parenteral nutrition solutions (TPN and PPN), intravenous products, controlled substances for incarcerated patients, and opioid antagonists and drug-disposal systems for community health initiatives under this code. The issuing bodies include state departments of corrections and county health authorities managing clinical supply chains with demanding delivery windows—parenteral nutrition bags within 24 hours of order, other IV products within 8 hours, and quarterly bulk shipments of naloxone and drug deactivation systems to designated health facilities. Washington State Department of Corrections and Seminole County, Florida represent the issuing-body mix visible in recent activity.

Washington State and Florida show the most recent activity under this code. The Washington State Department of Corrections issued RFQQK13020 in September 2026 for parenteral products, services, and equipment to supply eight correctional facilities across three regions (West, Central, East), with an RFQ response deadline of October 7, 2026 and a pre-bid conference on September 23, 2026; DOC anticipated selecting up to three contractors per region for the initial contract term running November 26, 2026 through June 30, 2030, with fixed pricing for the first two years and set-aside aspirations of 5% small and diverse businesses. Seminole County, Florida issued IFB60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. Both procurements require demonstrated experience with clinical supply protocols, compliance with federal and state regulations (E-Verify, drug-free workplace certification, insurance requirements including professional and cyber liability), and fixed-price delivery models.